

2019 Future of Myocardial Fibrosis R&D Pipeline Drugs and Companies- Analysis of Global Myocardial Fibrosis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/208881BA281EN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 208881BA281EN

Abstracts

The global demand for Myocardial Fibrosis treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Myocardial Fibrosis pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Myocardial Fibrosis pipeline companies from advancing their products into Phase 3 or Phase 4.

Myocardial Fibrosis Report Description

The H1 2019 pipeline review report on Myocardial Fibrosis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Myocardial Fibrosis pipeline compounds.

The Myocardial Fibrosis pipeline guide presents information on all active drugs currently being developed for Myocardial Fibrosis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Myocardial Fibrosis pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Myocardial Fibrosis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Myocardial Fibrosis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Myocardial Fibrosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Myocardial Fibrosis pipeline report includes

An overview of Myocardial Fibrosis disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Myocardial Fibrosis pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Myocardial Fibrosis pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Myocardial Fibrosis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL MYOCARDIAL FIBROSIS PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Myocardial Fibrosis Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Myocardial Fibrosis pipeline, H1- 2019
- 3.5 Mechanism of Action wise Myocardial Fibrosis Pipeline Candidates

4. APOLLO THERAPEUTICS LLC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 4.1 Apollo Therapeutics LLC Business Profile
- 4.2 Apollo Therapeutics LLC Myocardial Fibrosis Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. EMBER THERAPEUTICS INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 5.1 Ember Therapeutics Inc Business Profile
- 5.2 Ember Therapeutics Inc Myocardial Fibrosis Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. EVOTEC AG MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 6.1 Evotec AG Business Profile
- 6.2 Evotec AG Myocardial Fibrosis Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. GALECTIN THERAPEUTICS INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 7.1 Galectin Therapeutics Inc Business Profile
- 7.2 Galectin Therapeutics Inc Myocardial Fibrosis Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. INVIVOSCIENCES INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 8.1 Invivosciences Inc Business Profile
- 8.2 Invivosciences Inc Myocardial Fibrosis Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. LEAD DISCOVERY CENTER GMBH MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 9.1 Lead Discovery Center GmbH Business Profile
- 9.2 Lead Discovery Center GmbH Myocardial Fibrosis Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation

- 9.2.1.5 Area
- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. MANDALMED INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 10.1 MandalMed Inc Business Profile
- 10.2 MandalMed Inc Myocardial Fibrosis Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. MERCK & CO INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 11.1 Merck & Co Inc Business Profile
- 11.2 Merck & Co Inc Myocardial Fibrosis Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action

11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. MIRAGEN THERAPEUTICS INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

12.1 Miragen Therapeutics Inc Business Profile

12.2 Miragen Therapeutics Inc Myocardial Fibrosis Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. NOVOMEDIX LLC MYOCARDIAL FIBROSIS PIPELINE DETAILS

13.1 NovoMedix LLC Business Profile

13.2 NovoMedix LLC Myocardial Fibrosis Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. PALATIN TECHNOLOGIES INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 14.1 Palatin Technologies Inc Business Profile
- 14.2 Palatin Technologies Inc Myocardial Fibrosis Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. PHARMAXIS LTD MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 15.1 Pharmaxis Ltd Business Profile
- 15.2 Pharmaxis Ltd Myocardial Fibrosis Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. PROMETIC LIFE SCIENCES INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 16.1 ProMetic Life Sciences Inc Business Profile
- 16.2 ProMetic Life Sciences Inc Myocardial Fibrosis Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer

- 16.2.1.3 Route of Administration
- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. TRACON PHARMACEUTICALS INC MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 17.1 TRACON Pharmaceuticals Inc Business Profile
- 17.2 TRACON Pharmaceuticals Inc Myocardial Fibrosis Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. VECTUS BIOSYSTEMS LTD MYOCARDIAL FIBROSIS PIPELINE DETAILS

- 18.1 Vectus Biosystems Ltd Business Profile
- 18.2 Vectus Biosystems Ltd Myocardial Fibrosis Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity

18.3 Current Status

18.4 Drug Overview

18.5 Drug Mechanism of Action

18.6 Clinical/Pre-clinical Trial Details

18.7 Latest Drug Developments

19. LATEST MYOCARDIAL FIBROSIS DRUG PIPELINE DEVELOPMENTS, 2019

20. APPENDIX

20.1 About Us

20.2 Sources and Methodology

20.3 Contact Information

I would like to order

Product name: 2019 Future of Myocardial Fibrosis R&D Pipeline Drugs and Companies- Analysis of Global Myocardial Fibrosis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/208881BA281EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/208881BA281EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970